News
Over the past week, AstraZeneca’s COVID-19 jab has been at the centre of disputes about vaccine efficiency both in older people, and against the...
NICE has issued final draft guidance recommending the routine use of Bristol Myers Squibb (BMS)’s Opdivo (nivolumab) as an option after surgery for...
Several European countries have continued to impose age restrictions on their rollouts of the Oxford University-AstraZeneca vaccine, despite WHO’s...
The FDA has approved Regeneron’s Evkeeza (evinacumab-dgnb) as an adjunct to other low-density lipoprotein cholesterol (LDL-C) lowering therapies to...
The rheumatoid arthritis drug tocilizumab can reduce the risk of death in severe COVID-19 patients and shorten the time spent in hospital, results...
Galapagos and Gilead have halted the ISABELA Phase III clinical studies for their autotaxin inhibitor ziritaxestat in patients with idiopathic...
NICE has recommended treatment options for severe pregnancy sickness for the first time, issuing recommendations in draft guidance published today.
The Cell and Gene Therapy Catapult (CGT Catapult) and Rentschler Biopharma have announced that Rentschler will establish their manufacturing...
The FDA has granted emergency use authorisation for Eli Lilly’s antibodies bamlanivimab (LY-CoV555) 700mg and etesevimab (LY-CoV016) 1400mg, to be...
Scientists advising the WHO have recommended the use of the Oxford-AstraZeneca COVID-19 vaccine in all adults, including those aged over 65.